Hepatocellular Carcinoma Clinical Trial
— INFICOfficial title:
"Pilot Study: Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway in the Management of a Patient Treated for Hepatocellular Carcinoma (HCC)"
This project is based on the assumption that the nurse coordinators of the centres have
common missions at each of the key stages of patient care. These missions make the care plan
more fluid and improve the quality and safety of care as well as the patient's prognosis.
The Hypothesis is that co-follow-up by a doctor and a nurse coordinator reduces time between
referral to treatment, average lengths of stay, unscheduled readmissions or early emergency
visits, compared to follow-up that does not involve a nurse coordinator.
Status | Recruiting |
Enrollment | 1000 |
Est. completion date | February 1, 2020 |
Est. primary completion date | February 1, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility |
Inclusion Criteria: - Centre with interventional radiology treatment - Active list of patients followed for a HCC of at least 70 / year - Reply to the feasibility questionnaire within 60 days from receipt of the email Exclusion Criteria: - Patient with a localized HCC diagnosis (BCLC A or B) - Hospitalised for a first interventional radiology treatment (radioembolisation, transarterial chemoembolization or percutaneous ablation) in one of the centres included in the study between July 1, 2017 and December 31, 2017 |
Country | Name | City | State |
---|---|---|---|
France | BEAUJON Hospital | Clichy-sous-Bois |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of the following missions of the coordinator Nurse | missions: o Initial contact of the patient with the expert centre Organisation of the MDT meeting Organisation of treatment and investigations Coordination between hospital professionals Link with community health professionals Follow-up (post-hospitalization, treatment side effects, etc.) Information, advice to patients Psychological support Implementation of care pathways Nursing research |
12 months | |
Secondary | Timeframe in days between The first contact with the centre and the first interventional radiology treatment. | Timeframe in days between The first contact with the centre and the first interventional radiology treatment. | 12 months | |
Secondary | Timeframe in days between : The first contact with the centre and the first presentation at a MDT meeting | Timeframe in days between : The first contact with the centre and the first presentation at a MDT meeting | 12 months | |
Secondary | Timeframe in days between : The first contact with the centre and the diagnostic consultation | Timeframe in days between : The first contact with the centre and the diagnostic consultation | 12 months | |
Secondary | Timeframe in days between :The first contact with the centre and discharge from the hospital | Timeframe in days between :The first contact with the centre and discharge from the hospital | 12 months | |
Secondary | Timeframe in days between :The interventional radiology procedure and the next one for the subgroup of patients who have multiple procedures during the follow-up period | Timeframe in days between :The interventional radiology procedure and the next one for the subgroup of patients who have multiple procedures during the follow-up period | 12 months | |
Secondary | Length of hospital stay for a first interventional radiology treatment in patients with HCC. | Length of hospital stay for a first interventional radiology treatment in patients with HCC. | 12 months | |
Secondary | Number of emergency unit visits during the first month following hospitalization for interventional radiology treatment for patients included in the study. | Number of emergency unit visits during the first month following hospitalization for interventional radiology treatment for patients included in the study. | 12 months | |
Secondary | Number of early unscheduled readmissions during the first month following interventional radiology treatment for patients included in the study. | Number of early unscheduled readmissions during the first month following interventional radiology treatment for patients included in the study. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 | |
Recruiting |
NCT05537402 -
LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
|
Phase 2 |